Table 3.
Clinical evaluation of essential tremor (ET) before and after 1 month of treatment with mirtazapine (30 mg/daily) (number of patients = 27)
| Before treatment | After treatment | p | |
|---|---|---|---|
| Resting tremor | – | – | – |
| Postural tremor | 2.11 ± 0.42a | 1.19 ± 0.56 | < 0.01 |
| Action tremor | |||
| C1: in alternating flexion/extension arm movements | 1.41 ± 0.64 | 0.74 ± 0.71 | < 0.01 |
| C2: in reaching a target (index/nose test) | 1.56 ± 0.75 | 0.89 ± 0.58 | < 0.01 |
| Orthostatic tremor | – | – | – |
| Tremor of the head | 0.96 ± 1.01 | 0.48 ± 0.70 | < 0.01 |
| Speech | 1.07 ± 0.96 | 0.59 ± 0.69 | < 0.01 |
| Writing | 1.67 ± 0.68 | 0.89 ± 0.70 | < 0.01 |
| Overall subjective disability | 2.15 ± 0.53 | 1.04 ± 0.65 | < 0.01 |
a
Values are means ± standard deviation of mean.